353 related articles for article (PubMed ID: 19364933)
1. Effect of anti-CD25 antibody daclizumab in the inhibition of inflammation and stabilization of disease progression in multiple sclerosis.
Bielekova B; Howard T; Packer AN; Richert N; Blevins G; Ohayon J; Waldmann TA; McFarland HF; Martin R
Arch Neurol; 2009 Apr; 66(4):483-9. PubMed ID: 19364933
[TBL] [Abstract][Full Text] [Related]
2. Regulatory T cells are reduced during anti-CD25 antibody treatment of multiple sclerosis.
Oh U; Blevins G; Griffith C; Richert N; Maric D; Lee CR; McFarland H; Jacobson S
Arch Neurol; 2009 Apr; 66(4):471-9. PubMed ID: 19364932
[TBL] [Abstract][Full Text] [Related]
3. Daclizumab in active relapsing multiple sclerosis (CHOICE study): a phase 2, randomised, double-blind, placebo-controlled, add-on trial with interferon beta.
Wynn D; Kaufman M; Montalban X; Vollmer T; Simon J; Elkins J; O'Neill G; Neyer L; Sheridan J; Wang C; Fong A; Rose JW;
Lancet Neurol; 2010 Apr; 9(4):381-90. PubMed ID: 20163990
[TBL] [Abstract][Full Text] [Related]
4. Daclizumab phase II trial in relapsing and remitting multiple sclerosis: MRI and clinical results.
Rose JW; Burns JB; Bjorklund J; Klein J; Watt HE; Carlson NG
Neurology; 2007 Aug; 69(8):785-9. PubMed ID: 17709711
[TBL] [Abstract][Full Text] [Related]
5. Daclizumab HYP versus Interferon Beta-1a in Relapsing Multiple Sclerosis.
Kappos L; Wiendl H; Selmaj K; Arnold DL; Havrdova E; Boyko A; Kaufman M; Rose J; Greenberg S; Sweetser M; Riester K; O'Neill G; Elkins J
N Engl J Med; 2015 Oct; 373(15):1418-28. PubMed ID: 26444729
[TBL] [Abstract][Full Text] [Related]
6. Intrathecal effects of daclizumab treatment of multiple sclerosis.
Bielekova B; Richert N; Herman ML; Ohayon J; Waldmann TA; McFarland H; Martin R; Blevins G
Neurology; 2011 Nov; 77(21):1877-86. PubMed ID: 22076546
[TBL] [Abstract][Full Text] [Related]
7. Daclizumab use in patients with pediatric multiple sclerosis.
Gorman MP; Tillema JM; Ciliax AM; Guttmann CR; Chitnis T
Arch Neurol; 2012 Jan; 69(1):78-81. PubMed ID: 22232346
[TBL] [Abstract][Full Text] [Related]
8. Humanized anti-CD25 (daclizumab) inhibits disease activity in multiple sclerosis patients failing to respond to interferon beta.
Bielekova B; Richert N; Howard T; Blevins G; Markovic-Plese S; McCartin J; Frank JA; Würfel J; Ohayon J; Waldmann TA; McFarland HF; Martin R
Proc Natl Acad Sci U S A; 2004 Jun; 101(23):8705-8. PubMed ID: 15161974
[TBL] [Abstract][Full Text] [Related]
9. Daclizumab for relapsing remitting multiple sclerosis.
Liu J; Wang LN; Zhan S; Xia Y
Cochrane Database Syst Rev; 2013 Dec; (12):CD008127. PubMed ID: 24363032
[TBL] [Abstract][Full Text] [Related]
10. Mitoxantrone: a review of its use in multiple sclerosis.
Scott LJ; Figgitt DP
CNS Drugs; 2004; 18(6):379-96. PubMed ID: 15089110
[TBL] [Abstract][Full Text] [Related]
11. A double-masked, randomized study to investigate the safety and efficacy of daclizumab to treat the ocular complications related to Behçet's disease.
Buggage RR; Levy-Clarke G; Sen HN; Ursea R; Srivastava SK; Suhler EB; Altemare C; Velez G; Ragheb J; Chan CC; Nussenblatt RB; Bamji AT; Sran P; Waldmann T; Thompson DJ
Ocul Immunol Inflamm; 2007; 15(2):63-70. PubMed ID: 17558830
[TBL] [Abstract][Full Text] [Related]
12. Safety and efficacy of daclizumab in relapsing-remitting multiple sclerosis: 3-year results from the SELECTED open-label extension study.
Gold R; Radue EW; Giovannoni G; Selmaj K; Havrdova E; Stefoski D; Sprenger T; Montalban X; Cohan S; Umans K; Greenberg SJ; Ozen G; Elkins J
BMC Neurol; 2016 Jul; 16():117. PubMed ID: 27461166
[TBL] [Abstract][Full Text] [Related]
13. Modulation of IL-2Rα with daclizumab for treatment of multiple sclerosis.
Wiendl H; Gross CC
Nat Rev Neurol; 2013 Jul; 9(7):394-404. PubMed ID: 23732529
[TBL] [Abstract][Full Text] [Related]
14. Daclizumab (anti-CD25) in multiple sclerosis.
Pfender N; Martin R
Exp Neurol; 2014 Dec; 262 Pt A():44-51. PubMed ID: 24768797
[TBL] [Abstract][Full Text] [Related]
15. Daclizumab for relapsing remitting multiple sclerosis.
Liu J; Wang L; Zhan SY; Xia Y
Cochrane Database Syst Rev; 2012 Apr; (4):CD008127. PubMed ID: 22513956
[TBL] [Abstract][Full Text] [Related]
16. CNS vasculitis in a patient with MS on daclizumab monotherapy.
Ohayon J; Oh U; Richert N; Martin J; Vortmeyer A; McFarland H; Bielekova B
Neurology; 2013 Jan; 80(5):453-7. PubMed ID: 23303850
[TBL] [Abstract][Full Text] [Related]
17. Daclizumab, an IL-2 modulating antibody for treatment of multiple sclerosis.
Sheridan JP; Robinson RR; Rose JW
Expert Rev Clin Pharmacol; 2014 Jan; 7(1):9-19. PubMed ID: 24308792
[TBL] [Abstract][Full Text] [Related]
18. Regulatory CD56(bright) natural killer cells mediate immunomodulatory effects of IL-2Ralpha-targeted therapy (daclizumab) in multiple sclerosis.
Bielekova B; Catalfamo M; Reichert-Scrivner S; Packer A; Cerna M; Waldmann TA; McFarland H; Henkart PA; Martin R
Proc Natl Acad Sci U S A; 2006 Apr; 103(15):5941-6. PubMed ID: 16585503
[TBL] [Abstract][Full Text] [Related]
19. Dendritic cell vaccination in combination with anti-CD25 monoclonal antibody treatment: a phase I/II study in metastatic melanoma patients.
Jacobs JF; Punt CJ; Lesterhuis WJ; Sutmuller RP; Brouwer HM; Scharenborg NM; Klasen IS; Hilbrands LB; Figdor CG; de Vries IJ; Adema GJ
Clin Cancer Res; 2010 Oct; 16(20):5067-78. PubMed ID: 20736326
[TBL] [Abstract][Full Text] [Related]
20. Daclizumab: Development, Clinical Trials, and Practical Aspects of Use in Multiple Sclerosis.
Baldassari LE; Rose JW
Neurotherapeutics; 2017 Oct; 14(4):842-858. PubMed ID: 28707278
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
